SecBot SecBot
8-K ·Filed Jun 29, 2026

RMTI

ROCKWELL MEDICAL, INC.
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0001628280-26-045866
8-K context-dependent: Items 3.03
Actionable Insight • Neutral

Monitor post-split trading for liquidity and potential Nasdaq compliance benefits. No immediate catalyst for price movement; the split is a mechanical adjustment.

DirectionNeutral
Confidencehigh
Horizonimmediate
Final — all horizons settled through T+60d
RMTI ▲ +45.90% at T+60d
NEUTRAL call +45.90% · α vs SPY +42.28% · entry $0.5874 → $0.8570
Entry = T+0 close
Jun 29, 2026
via day close
T+1d
-6.28%
call -6.28% · α -7.06%
$0.5505
settled 4mo ago
T+5d
+3.85%
call +3.85% · α +2.94%
$0.6100
settled 4mo ago
T+20d
+19.00%
call +19.00% · α +19.02%
$0.6990
settled 3mo ago
T+60d
+45.90%
call +45.90% · α +42.28%
$0.8570
settled 5w ago

Price Chart

Loading chart...

Executive Summary

Rockwell Medical filed an 8-K announcing a 1-for-10 reverse stock split effective July 1, 2026, approved by stockholders. The split is a routine capital structure adjustment to maintain Nasdaq listing compliance, with no material financial impact.

Key Facts

  • Reverse stock split ratio of 1-for-10, effective 12:01 a.m. ET on July 1, 2026.
  • Approved by stockholders at the annual meeting on June 12, 2026.
  • No fractional shares will be issued; cash paid in lieu based on closing price on June 30, 2026.
  • Proportionate adjustments to equity awards, Series X Convertible Preferred Stock conversion price, and warrants.
  • Common stock continues trading on Nasdaq under symbol RMTI with new CUSIP 774374409.

Financial Impact

Reverse stock split reduces outstanding share count by 90% with no change to par value or total equity; no dollar amounts disclosed.

share countstock priceoutstanding equity awardswarrant exercise prices

Risk Factors

  • Reverse splits can be perceived as a sign of financial distress, potentially pressuring sentiment.
  • Cash-in-lieu of fractional shares may create minor dilution for small holders.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-045866
Document: 0001628280-26-045866-index.html0001628280-26-045866
Document: 0001628280-26-045866.txt0001628280-26-045866
5 reports for RMTI
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for RMTI — sortable, filterable
TypeNow
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 2/10
$7.83awaiting T+60—$6.97 (−10.86%)
Jul 20, 2026
14w ago
8-K
NEUTRAL ★ 2/10
$6.30 $7.85▲ +24.70%▲ +19.86%$6.97 (+10.80%)
Jun 29, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$0.5874 $0.8570▲ +45.90%▲ +42.28%$6.97 (+1087.44%)
May 8, 2026
24w ago
8-K
BEARISH ★ 7/10
$8.40 $7.26▲ +13.57%▲ +17.96%$6.97 (+16.96%)
May 7, 2026
24w ago
8-K
NEUTRAL ★ 2/10
$7.80 $7.23▼ −7.31%▼ −11.14%$6.97 (−10.58%)
Showing 5 of 5

US Market Status

Market Open — Closes in 3h 15m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026